09.09.13
ChromaDex Corp., Irvine, CA, will enter a three-year marketing deal worth at least $3.5 million with Thorne Research Inc., Sandpoint, ID, for ChromaDex’s recently launched NiagenT, its novel, patented, branded nicotinamide riboside (NR) ingredient. Under the terms of the agreement, Thorne Research receives marketing rights for NiagenT for use in nutritional supplements exclusively for the direct to healthcare practitioner channel in the U.S. and Canada. ChromaDex will receive a royalty on sales of Thorne Research products that will contain NiagenT. In addition, Thorne Research will collaborate with ChromaDex on future human clinical trials of NiagenT.
According to the companies, NiagenT has the potential to become a part of the portfolio of B-vitamin ingredients included in products serving multi-billion dollar markets such as multivitamins, nutraceuticals, weight loss, energy drinks, sports nutrition, meal replacements, infant formula and food and beverage products.
According to the companies, NiagenT has the potential to become a part of the portfolio of B-vitamin ingredients included in products serving multi-billion dollar markets such as multivitamins, nutraceuticals, weight loss, energy drinks, sports nutrition, meal replacements, infant formula and food and beverage products.
